Concurrent and Adjuvant PD1 Treatment Combined With Chemo-radiotherapy for High-risk Nasopharyngeal Carcinoma

NCT04453826 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

388

Enrollment

OTHER

Sponsor class

Conditions

Nasopharyngeal Cancer
Chemotherapy
Radiotherapy
PD-1 Therapy

Interventions

DRUG: Camrelizumab plus chemo-radiotherapy
DRUG: Chemo-radiotherapy alone

Sponsor

Sun Yat-sen University

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]